Improved hemocompatibility by modifying acellular blood vessels with bivalirudin and its biocompatibility evaluation
Research article published in J Biomed Mater Res A (2021)
Abstract
The incidence rate of cardiovascular diseases is increasing year by year. The demand for coronary artery bypass grafting has been very large. Acellular blood vessels have potential clinical application because of their natural vascular basis, but their biocompatibility and anticoagulant energy need to be improved. We decellularized the abdominal aorta of SD rats, and then modified with bivalirudin via polydopamine. The mechanical properties, blood compatibility, cytocompatibility, immune response, and anticoagulant properties were evaluated, and then the bivalirudin-modified acellular blood vessels were implanted into rats for remodeling evaluation in vivo. The results we got show that the bivalirudin-modified acellular blood vessels showed good cytocompatibility and blood compatibility, and its anti-inflammatory trend was dominant in the immune response. After 3 months of transplantation, the bivalirudin-modified acellular blood vessels did not easily form thrombus. It was not easy to form calcification and could make the host cells grow better. Through vascular stimulation and immunofluorescence test, we found that vascular smooth muscle cells and endothelial cells proliferated well in the bivalirudin group. Bivalirudin-modified acellular blood vessels provided new idea for small diameter tissue engineering blood vessels, and may become a potential clinical substitute for small-diameter vascular grafts.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Bivalirudin-modified acellular blood vessels show good cytocompatibility, blood compatibility, anti-inflammatory profile, and improved remodeling in rat models.
Por qué esto importa para la hirudoterapia
Este estudio descelularizó la aorta abdominal de rata (Sprague-Dawley), la modificó con bivalirudina mediante polidopamina, y evaluó las propiedades mecánicas, la compatibilidad sanguínea, la citocompatibilidad, la respuesta inmune y las propiedades anticoagulantes, seguido de implantación in vivo en ratas. Los vasos sanguíneos acelulares modificados con bivalirudina mostraron buena citocompatibilidad y compatibilidad sanguínea, una tendencia antiinflamatoria dominante, reducción del trombo y la calcificación a los 3 meses, y buena proliferación de células de músculo liso vascular y células endoteliales. La bivalirudina está indexada bajo el término MeSH 'Hirudins', lo que proporciona la única conexión a nivel de resumen con el campo de los anticoagulantes de la sanguijuela. ADVERTENCIA: El resumen no describe la relación de la bivalirudina con la hirudina derivada de la sanguijuela, y el estudio no involucra sanguijuelas, terapia con sanguijuelas ni secretoma de sanguijuela; se trata de un estudio de ingeniería tisular en animales (rata) y los hallazgos no pueden aplicarse a la hirudoterapia.
Citación
Improved hemocompatibility by modifying acellular blood vessels with bivalirudin and its biocompatibility evaluation.
Du P et al. · J Biomed Mater Res A, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026